Dianthus Therapeutics, Inc.
DNTH
Rank in Stocks
#3909
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Share Price
$75.08
Market Cap
$4.20B
Change (1 day)
4.15%
Change (1 year)
110.60%
Country
US
Trade Dianthus Therapeutics, Inc. (DNTH)
Category
Healthcare
P/B ratio for Dianthus Therapeutics, Inc. (DNTH)
P/B ratio as of October 2026 TTM: 3.57
According to Dianthus Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 3.57. At the end of 2023 the company had a P/B ratio of 0.32.
P/B ratio history for Dianthus Therapeutics, Inc. from 2016 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 3.57 | 73.49% |
| 2024 | 2.06 | 549.15% |
| 2023 | 0.32 | -159.46% |
| 2022 | -0.53 | -137.87% |
| 2021 | 1.41 | -41.09% |
| 2020 | 2.39 | -39.79% |
| 2019 | 3.97 | 204.85% |
| 2018 | 1.30 | -87.23% |
| 2017 | 10.21 | -82.03% |
| 2016 | 56.80 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | 74.91% |
US
|
|
| 13.2547 | 270.87% |
US
|
|
| 4.208 | 17.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 72.99% |
NL
|
